In Crohn's disease the optimal duration of azathioprine treatment is still controversial and for ulcerative colitis only limited data are available to support its efficacy. Charts of 1176 patients with IBD from 16 European centers were analyzed. Flare incidences and steroid dosages were assessed for the time before and during treatment and after discontinuation. Within the first 4 years, azathioprine suppressed flare incidence and steroid consumption in both diseases (P <0.001). While in CD discontinuation after 3-4 years did not lead to reactivation, this was the case in UC. However, continuation beyond 4 years further improved clinical activity in CD and steroid requirement in both diseases (P <0.001). Discontinuation of azathioprine may ...
BACKGROUND: Beneficial response to first-line immunosuppressive azathioprine in patients with inflam...
The treatment of moderate-to-severe steroid-dependent Crohn's disease has been a challenging issue f...
BACKGROUND: Low-dose azathioprine with allopurinol (LDAA) has been proposed as a potent therapy in i...
BACKGROUND: There are limited data on factors predicting response to azathioprine and uncertainty re...
Background: There is no consensus on the recommended duration of and optimal time to stop azathiopri...
Characterisation of an Inflammatory Bowel Disease (IBD) population treated with azathioprine (AZA) a...
International audienceBACKGROUND AND AIMS: Long-term benefits of combination therapy (combotherapy) ...
OBJECTIVES: Whether the duration of maintenance treatment with azathioprine (AZA) affects the outcom...
OBJECTIVES: Whether the duration of maintenance treatment with azathioprine (AZA) affects the outcom...
Azathioprine and 6-mercaptopurine are effective drugs in the management of steroid dependent and chr...
This interim report on a controlled therapeutic trial of azathioprine in ulcerative colitis deals wi...
Eighty patients, all of whom were suffering from a frank clinical attack of ulcerative colitis, were...
BACKGROUND: The management of patients with inflammatory bowel disease who are resistant to or intol...
Ulcerative colitis (UC) and Crohn’s disease (CD) are chronic inflammatory disorders, which require l...
Background: Infliximab (IFX) has demonstrated effectiveness for inducing 12-month steroid-free clini...
BACKGROUND: Beneficial response to first-line immunosuppressive azathioprine in patients with inflam...
The treatment of moderate-to-severe steroid-dependent Crohn's disease has been a challenging issue f...
BACKGROUND: Low-dose azathioprine with allopurinol (LDAA) has been proposed as a potent therapy in i...
BACKGROUND: There are limited data on factors predicting response to azathioprine and uncertainty re...
Background: There is no consensus on the recommended duration of and optimal time to stop azathiopri...
Characterisation of an Inflammatory Bowel Disease (IBD) population treated with azathioprine (AZA) a...
International audienceBACKGROUND AND AIMS: Long-term benefits of combination therapy (combotherapy) ...
OBJECTIVES: Whether the duration of maintenance treatment with azathioprine (AZA) affects the outcom...
OBJECTIVES: Whether the duration of maintenance treatment with azathioprine (AZA) affects the outcom...
Azathioprine and 6-mercaptopurine are effective drugs in the management of steroid dependent and chr...
This interim report on a controlled therapeutic trial of azathioprine in ulcerative colitis deals wi...
Eighty patients, all of whom were suffering from a frank clinical attack of ulcerative colitis, were...
BACKGROUND: The management of patients with inflammatory bowel disease who are resistant to or intol...
Ulcerative colitis (UC) and Crohn’s disease (CD) are chronic inflammatory disorders, which require l...
Background: Infliximab (IFX) has demonstrated effectiveness for inducing 12-month steroid-free clini...
BACKGROUND: Beneficial response to first-line immunosuppressive azathioprine in patients with inflam...
The treatment of moderate-to-severe steroid-dependent Crohn's disease has been a challenging issue f...
BACKGROUND: Low-dose azathioprine with allopurinol (LDAA) has been proposed as a potent therapy in i...